Hyperfine Inc (HYPR)vsNovartis AG ADR (NVS)
HYPR
Hyperfine Inc
$1.87
+12.65%
HEALTHCARE · Cap: $163.54M
NVS
Novartis AG ADR
$146.57
-0.87%
HEALTHCARE · Cap: $282.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 417050% more annual revenue ($56.58B vs $13.56M). NVS leads profitability with a 23.9% profit margin vs -262.3%. NVS earns a higher WallStSmart Score of 51/100 (C-).
HYPR
Avoid25
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HYPR.
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$146.57
$36.97 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 128.0% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -79.0% — below average capital efficiency
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : HYPR
The strongest argument for HYPR centers on Revenue Growth. Revenue growth of 128.0% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : HYPR
The primary concerns for HYPR are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Key Dynamics to Monitor
HYPR profiles as a hypergrowth stock while NVS is a declining play — different risk/reward profiles.
HYPR carries more volatility with a beta of 1.06 — expect wider price swings.
HYPR is growing revenue faster at 128.0% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 25/100), backed by strong 23.9% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Hyperfine Inc
HEALTHCARE · MEDICAL DEVICES · USA
Hyperfine Inc. is an innovative leader in medical technology, renowned for developing the first FDA-cleared portable MRI system that revolutionizes access to imaging at the point of care. By delivering high-quality imaging directly at the bedside, Hyperfine enhances patient care and streamlines clinical decision-making, addressing the growing demand for efficient and accessible diagnostic solutions. The company's focus on cost efficiency and patient convenience uniquely positions it within the evolving healthcare landscape, making it a compelling opportunity for institutional investors seeking to invest in transformative healthcare advancements.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?